T cell exhaustion markers, such as T cell immunoglobulin and mucin-domain-containing protein-3 (TIM-3) and lymphocyte activation gene-3 (LAG-3), can also be targeted with antibodies to reduce T cell dysfunction and increase the number of activated tumor-killing T cells [39,40]. This evidence concerns the gene LAG3 and neoplasm.